31 East 62nd Street
New York, NY 10065
United States
212 672 9100
https://www.siga.com
Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 45
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Daniel J. Luckshire | Executive VP, CFO & Secretary | 1,42M | N/D | 1971 |
Dr. Dennis E. Hruby Ph.D. | Executive VP & Chief Scientific Officer | 1,41M | N/D | 1952 |
Dr. Jay K. Varma M.D. | Executive VP, Chief Medical Officer & Director | 1,04M | N/D | 1972 |
Dr. Diem Nguyen M.B.A., Ph.D. | CEO & Director | N/D | N/D | 1972 |
Ms. Tove C. Bolken | Senior VP of Operations & Chief Supply Chain Officer | N/D | N/D | N/D |
Mr. Herb Vloedman | Senior VP & Chief Information Officer | N/D | N/D | N/D |
Mr. Lawrence R. Miller Esq., J.D. | General Counsel | N/D | N/D | 1968 |
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
L'ISS Governance QualityScore di SIGA Technologies, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 9; diritti degli azionisti: 2; retribuzione: 8.